Parkinson’s disease is a progressive neurological disorder that is caused by the degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement, resulting in tremors, slowness of movement, rigidity, and impaired balance and coordination – the primary symptoms of the disease.

The gold standard for evaluating Parkinson’s disease symptoms has primarily relied on subjective assessments during in-clinic visits using rating scales like the Unified Parkinson’s Disease Rating Scale (UPDRS). This approach, however, has specific limitations, leading to often incomplete disease progression evaluation. Over the last decades, various methods have been developed to assess the patients' motor symptoms more accurately.

Today is World Parkinson's Day, a day dedicated to raising awareness for the disease and paying tribute to people living with the condition every day! Parkinson’s disease is the fastest-growing neurological disorder in the world, affecting people of all races and cultures.

April marks Parkinson’s Awareness Month, a time dedicated to increasing awareness about and elevating the conversation around Parkinson's disease, a neurological disorder that progressively impairs movement and function, affecting millions worldwide.

The Paracelsus Nordseeklinik Helgoland's specialist neurological department, headed by Dr. Annette Rogge, offers a multimodal therapy program for patients with Parkinson's disease. To provide her patients with the best possible treatment tailored to their individual disease progression, Dr. Rogge opted for an objective assessment of motor symptoms using the measurement and analysis services provided by Adamant Health.

On Saturday, we had the honor to celebrate the Finnish Movement Disorders Association’s 40th anniversary together with over 200 guests, including people diagnosed with movement disorders and their relatives.

With the current practice of treating patients with Parkinson’s disease through in-person clinical examination, clinicians have only a limited amount of time available for observing and examining the patients and are heavily relying on patient reporting for symptoms and overall well-being.

Adamant Health is participating in the 22nd Annual Scandinavian Meeting on Parkinson’s Disease and Related Disorders taking place from 26–27 April 2024 in Helsinki, Finland. Meet us at our booth to learn more about how our technology can help you make more informed treatment decisions for your Parkinson's patients!

Adamant Health is participating in the Deutscher Kongress für Parkinson und Bewegungsstörungen 2024 taking place from 25 to 27 April 2024 in Rostock, Germany. Meet us at our booth to learn more about our data-driven approach for managing Parkinson’s disease!

Are you passionate about software development? Do you seek a meaningful job to help people suffering from Parkinson’s disease? We are looking for a Software Developer to join our diverse and passionate team of professionals to revolutionize the care of Parkinson's disease.

2023 has been an exciting year for Adamant Health. With the year drawing to an end, we’d like to take this opportunity to thank you for your cooperation and support. As we pause to spend time with family and friends during the holidays, we wish you a happy, healthy holiday season and a wonderful New Year!

The DGN-Kongress in Berlin was the venue for this year’s annual meeting of the German Neurological Society from November 8 to 11, 2023. Launching its presence in Germany, Adamant Health participated for the first time as an advanced technology provider with a booth to promote our concept for accurate and detailed symptom measurement.

Movement disorders can be especially difficult to diagnose, treat, and understand. In the next 30 years, there will be a strong increase in the number of people affected by movement disorders and that is why we are promoting #MoveDisorder awareness.

Parkinson’s disease is a neurodegenerative disease without any curative treatment or neuroprotective or disease-halting drugs. It is characterized by motor symptoms that are still quantified mostly by subjective methods. Studies have shown that combining surface electromyography (EMG) and kinematic measurements can lead to objective quantification of a patient’s neuromuscular and motor function.

A new study on wearable monitoring of negative myoclonus within the home environment is now available. The research was conducted in collaboration between the University of Eastern Finland, Kuopio University Hospital (KUH) - Kuopion yliopistollinen sairaala (KYS), UCL Queen Square Institute of Neurology and Adamant Health.

Meet us at the Neurologipäivät 2023 to learn more about our data-driven approach for managing Parkinson’s disease, and how it will help people with Parkinson’s to get the best treatment possible – improving their quality of life!

Adamant Health is participating in the 96. Kongress der Deutschen Gesellschaft für Neurologie taking place from 8 to 11 November 2023 in Berlin, Germany. Meet us at booth B17 to learn more about our data-driven approach for managing Parkinson’s disease!

We’ve just returned from this year’s International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen and are strongly encouraged by the valuable and in-depth discussions we had there. We feel it is absolutely key to continue educating the market about the EMG signal’s role in quantifying the neurophysiological basis of motor symptoms and why it provides a more accurate picture.

Adamant Health has developed a technology and service that will revolutionize the care of Parkinson's disease and other movement disorders. Business Kuopio has interviewed Adamant Health's founders Paulus Carpelan and Saara Rissanen.

Adamant Health is growing and entering a new phase in its journey, and we are looking for a Software Developer to strengthen our team. In this role you are developing mobile applications enabling our unique Parkinson’s disease measurement, connecting data to our cloud service, and communicating analyzed information back to the patient.